Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing.
about
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinibManaging Patients With Myelofibrosis in the Era of Janus Kinase InhibitorsGenetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis.Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasmsRuxolitinib: a review of its use in patients with myelofibrosis.Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients.Managing patients with myelofibrosis and low platelet counts.Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.Generation and characterization of a JAK2V617F-containing erythroleukemia cell line.Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia.Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice.The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL.Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.Recommendations on the use of ruxolitinib for the treatment of myelofibrosis.Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis.A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis.
P2860
Q26750696-51252C01-AC0E-4828-9CBC-43DC778C7F57Q28073296-CB6DDB75-8014-4828-BCE4-101BDF6FADE5Q33417004-7756BD0A-AEA2-4B5A-ACDD-A600FF92E8FFQ33417217-E2B81826-DE0C-4F06-BF44-ECE29B60844DQ33419865-55F2BA7E-1B90-403D-AEC6-5D2CA2C8D807Q33422507-351D354A-B895-40A6-A99A-5D53D160321EQ33432406-ED6F9C88-0FA6-4615-9257-3940BC357126Q33439559-B1FCCC62-22B2-4815-97F6-98A37410049DQ33921220-F803B594-516B-4789-86F4-90B1E251A418Q35188877-12C5B21E-8E66-43B7-90CD-E9ACC8A0DDBEQ36305314-E3682C8C-4EA4-41F5-AAB4-C9314AD49982Q37715790-FC5AE468-64ED-4DEA-9DAF-7AA67B7101DFQ38403573-00B9ED37-43B2-449F-A3D1-DA9D2AD461F4Q41571058-8C709C5D-CB46-4998-9880-AAAB2F5E533FQ45236578-C3F0BF34-9D19-4B9B-A4B8-A34661C7C0D0Q47784419-5BF7F4EB-53B3-4C06-A9BC-819BF483710FQ47815810-F5CEB834-A732-4E47-8A53-6488C37F0B56Q48062723-2FEC9E4B-F552-4EEA-BAEC-37D9D93F0358Q51111145-275F395E-0A51-4FCA-9C38-C52F81F19923Q53164149-3BC41DD5-1243-409F-92A2-A5B99185677A
P2860
Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Optimizing management of ruxol ...... eed for individualized dosing.
@ast
Optimizing management of ruxol ...... eed for individualized dosing.
@en
type
label
Optimizing management of ruxol ...... eed for individualized dosing.
@ast
Optimizing management of ruxol ...... eed for individualized dosing.
@en
prefLabel
Optimizing management of ruxol ...... eed for individualized dosing.
@ast
Optimizing management of ruxol ...... eed for individualized dosing.
@en
P2860
P356
P1476
Optimizing management of ruxol ...... eed for individualized dosing.
@en
P2093
Ruben A Mesa
P2860
P2888
P356
10.1186/1756-8722-6-79
P5008
P577
2013-10-22T00:00:00Z
P5875
P6179
1005055006